Biolytx Pharmaceuticals targets drug-resistant bacteria
OKLAHOMA CITY — In 2004, i2E launched a “Meet the Scientist” speaker series in which Oklahoma researchers presented their findings to a local audience that was eager to hear about the potential of scientific discoveries.
The first “Meet the Scientist” presentation featured Dr. Anne Pereira, who was then an associate professor in the Department of Pathology at the University of Oklahoma College of Medicine.
Pereira discussed her groundbreaking research the discovery of a peptide based on a naturally occurring protein called CAP37. The CAP37 peptide showed potential to kill bacteria that have become resistant to standard antibiotics used around the world.
“The peptide is based on a protein that is naturally found in the human body and its function is to kill bacteria,” Pereira said.
Pereira is now dean of the OU Health Sciences Center Graduate College and associate dean for research at the OU College of Pharmacy. Her work has led to 18 patents and a new Oklahoma-born company, Biolytx Pharmaceuticals Corporation, that got its start at that first “Meet the Scientist” presentation.